Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus sales forecast. Shares of SENS fell nearly 12% at 65¢ apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — stayed relatively even. The Germantown, Maryland–based implantable continuous glucose monitor […]
Senseonics
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Data supports safety and accuracy of Senseonics 365-day CGM
Senseonics (NYSE:SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM). Germantown, Maryland-based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just […]
UnitedHealthcare to cover Senseonics Eversense E3 CGM
Senseonics (NYSE:SENS) announced that UnitedHealthcare intends to begin providing coverage for its Eversense E3 CGM. Coverage of the continuous glucose monitor for people with type 1 and insulin-requiring type 2 diabetes goes into effect on July 1, 2023. UnitedHealthcare, the largest health insurance company in the U.S., covers more than 45 million lives. Its offerings […]
Senseonics stock rises after hours on Street-beating Q1
Senseonics (NYSE:SENS) shares ticked up after hours on first-quarter results that topped the consensus forecast. Shares of SENS rose 1.9% at 66¢ apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.4%. The Germantown, Maryland-based company posted profits […]
Ascensia expands payment program for Senseonics Eversense E3 CGM
Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM. Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable […]
Senseonics announces first pediatric 365-day CGM insertion
Senseonics (NYSE:SENS) announced that the first pediatric study participant received an Eversense 365-day CGM insertion. The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy […]
Senseonics announces equity grants to employees under inducement plan
Senseonics (NYSE:SENS) announced today that it made equity grants to new employees under its 2019 inducement plan. The Germantown, Maryland-based long-term continuous glucose monitor (CGM) maker made these grants in accordance with NYSE requirements. On April 4, 2023, Senseonics granted 13 new non-executive employees non-qualified stock options. These options enable the employees to purchase an aggregate […]
Senseonics projects more than 20% growth in 2023
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that beat the consensus forecast. Shares of SENS rose 1.7% at 96¢ apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.7%. The Germantown, Maryland-based long-term implantable CGM […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]